Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2016

01-08-2016 | Original Article

Modeling and predicting drug resistance rate and strength

Authors: R. Fullybright, A. Dwivedi, I. Mallawaarachchi, B. Sinsin

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2016

Login to get access

Abstract

Drug resistance has been worsening in human infectious diseases medicine over the past several decades. Our ability to successfully control resistance depends to a large extent on our understanding of the features characterizing the process. Part of that understanding includes the rate at which new resistance has been emerging in pathogens. Along that line, resistance data covering 90 infectious diseases, 118 pathogens, and 337 molecules, from 1921 through 2007, are modeled using various statistical tools to generate regression models for the rate of new resistance emergence and for cumulative resistance build-up in pathogens. Thereafter, the strength of the association between the number of molecules put on the market and the number of resulting cases of resistance is statistically tested. Predictive models are presented for the rate at which new resistance has been emerging in infectious diseases medicine, along with predictive models for the rate of cumulative resistance build-up in the aggregate of 118 pathogens as well as in ten individual pathogens. The models are expressed as a function of time and/or as a function of the number of molecules put on the market by the pharmaceutical industry. It is found that molecules significantly induce resistance in pathogens and that new or cumulative drug resistance across infectious diseases medicine has been arising at exponential rates.
Appendix
Available only for authorised users
Literature
2.
go back to reference ECDC Antimicrobial Resistance and Healthcare-Associated Infections Programme (2009) Antibiotic resistance in Europe: the challenges ahead. Euro Surveill 14(45). pii: 19405 ECDC Antimicrobial Resistance and Healthcare-Associated Infections Programme (2009) Antibiotic resistance in Europe: the challenges ahead. Euro Surveill 14(45). pii: 19405
5.
go back to reference Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S et al (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763–1771CrossRefPubMed Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S et al (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763–1771CrossRefPubMed
6.
go back to reference Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C et al (2007) National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin Infect Dis 45:1132–1140CrossRefPubMed Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C et al (2007) National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin Infect Dis 45:1132–1140CrossRefPubMed
Metadata
Title
Modeling and predicting drug resistance rate and strength
Authors
R. Fullybright
A. Dwivedi
I. Mallawaarachchi
B. Sinsin
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2659-z

Other articles of this Issue 8/2016

European Journal of Clinical Microbiology & Infectious Diseases 8/2016 Go to the issue